Strategic Focus Targeted radiopharmaceuticals for oncology with a theranostic approach, enabling dual use of the same molecule for imaging and therapy, which can be leveraged to offer integrated diagnostic and treatment solutions to cancer centers.

Lead Program Momentum Lead product CAM-H2 in Phase I/II targeting HER2-positive tumors, presenting a near-term clinical milestone alignment for collaboration, co-development, or licensing discussions with academic centers and pharma partners.

Academic Access Academic Access Program for CAM-FAP-Ga-68 signals opportunities to engage universities and research cores for early-access studies, clinical data generation, and prospective partnerships that can broaden validation and visibility.

Strategic Partnerships Past collaborations with Eckert & Ziegler and Orchestra Life Sciences indicate openness to distribution, lead-212 isotope supply, and regional expansion, suggesting sales plays around radiopharmaceutical sourcing and geographic market entry.

Growth Readiness Well-funded profile with substantial funding and a lean employee base positions the company for rapid business development activities; potential buyers and licensees may include mid-sized biotech firms seeking to accelerate radiopharmaceutical portfolios and pipeline validation.